GlassScriptPhysician profile
Andrew Mcgehee
NPI 1235759085
$4,825.31
in general payments reported to CMS, 2019-2025
31 companies · $2,474 in 2025
The $2,474 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $338 · 2024: $2,014 · 2025: $2,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,825.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $562.34 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $550.53 | 2023-2025 | |
| Lilly USA, LLC | $538.68 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.28 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $363.52 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $314.19 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $279.18 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $153.61 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $144.74 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.20 | 2025 | Caplyta |
| Antares Pharma, INC. | $137.22 | 2024-2025 | Xyosted |
| Shield Therapeutics INC | $134.19 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.90 | 2023-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $132.03 | 2024-2025 | |
| Lundbeck LLC | $130.32 | 2024-2025 | Vyepti, Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $128.22 | 2023-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $79.74 | 2024-2025 | |
| Exact Sciences Corporation | $75.42 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $64.86 | 2024-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $62.51 | 2025 | |
| Inspire Medical Systems, INC. | $58.02 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $56.89 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $36.01 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $33.95 | 2023-2025 | Trintellix |
| Baxter Healthcare | $20.64 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Halozyme INC | $19.48 | 2023 | |
| Daiichi Sankyo INC. | $18.76 | 2025 | Injectafer |
| Sumitomo Pharma America, INC. | $18.17 | 2024 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $17.05 | 2025 | Strensiq |
| Phathom Pharmaceuticals, INC. | $15.43 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.23 | 2023 | Gardasil 9, Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mcgehee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.